Teva Pharmaceutical Industries (TEVA) Tax Provisions (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Tax Provisions came in at $121.0 million in Q2 2026, up 255.13% YoY from $34.1 million in Q2 2025, and up 80.6% on a QoQ basis from $67.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Tax Provisions (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Tax Provisions data on file, last reported at $121.0 million in Q2 2026.
- Quarterly Tax Provisions rose 255.13% year-over-year to $121.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.0 million (down 87.1% YoY) and the FY2025 annual result came in at -$180.0 million, down 126.63% from the prior year.
- Tax Provisions climbed to $121.0 million in Q2 2026, from $67.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $630.0 million in Q2 2024 to a low of -$900.0 million in Q2 2022.
- A 5-year average of $1.9 million and a median of $34.5 million in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2024 — Tax Provisions soared 4037.5% — and 2025, when it sank 1492.86%.
- Tracing TEVA's Tax Provisions over 5 years: stood at $149.0 million in 2022, then tumbled by 72.48% to $41.0 million in 2023, then tumbled by 31.71% to $28.0 million in 2024, then slumped by 1492.86% to -$390.0 million in 2025, then surged by 131.03% to $121.0 million in 2026.
- The last three Tax Provisions figures came in at $121.0 million (Q2 2026), $67.0 million (Q1 2026), and -$390.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.64 Bn | 2.15 Bn | 121.00 Mn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | -310.32 Mn |
| 5 | United Therapeutics | 22.26 Bn | 19.60 Bn | 683.80 Mn | 39.70 Mn |
| 6 | Viatris | 18.85 Bn | 17.96 Bn | 1.46 Bn | 54.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 17.80 Mn |
| 8 | Elanco Animal Health | 12.15 Bn | 11.62 Bn | 798.00 Mn | 2.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.28 Bn | 7.62 Bn | 397.90 Mn | -2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 121.00 Mn |
| Mar 31, 2026 | 67.00 Mn |
| Dec 31, 2025 | -390.00 Mn |
| Sep 30, 2025 | 214.00 Mn |
| Jun 30, 2025 | -78.00 Mn |
| Mar 31, 2025 | 74.00 Mn |
| Dec 31, 2024 | 28.00 Mn |
| Sep 30, 2024 | 69.00 Mn |
| Jun 30, 2024 | 630.00 Mn |
| Mar 31, 2024 | -52.00 Mn |
| Dec 31, 2023 | 41.00 Mn |
| Sep 30, 2023 | -12.00 Mn |
| Jun 30, 2023 | -16.00 Mn |
| Mar 31, 2023 | -19.00 Mn |
| Dec 31, 2022 | 149.00 Mn |
| Sep 30, 2022 | 107.00 Mn |
| Jun 30, 2022 | -900.00 Mn |
| Mar 31, 2022 | 2.00 Mn |
| Dec 31, 2021 | -24.00 Mn |
| Sep 30, 2021 | 76.00 Mn |